ReviewActa neurologica Scandinavica2021
The potential neurological effect of the COVID-19 vaccines: A review.
Review in Acta neurologica Scandinavica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review.Human vaccines & immunotherapeutics · 2022Pooled it
- A systematic review of cases of CNS demyelination following COVID-19 vaccination.Journal of neuroimmunology · 2022Pooled it
- Antioxidant Nutraceuticals: Their Adjunct Role in the Management of COVID-19 Infections and Post-COVID Syndrome.Infectious disorders drug targets · 2025Review
- Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.Scientific reports · 2024Article
- Spontaneous spinal epidural haematoma following COVID-19 vaccination: a case report.Annals of medicine and surgery (2012) · 2024Article
- A case of trigeminal neuralgia that occurred after COVID-19 vaccination.Central-European journal of immunology · 2024Article
- Pulmonary capillaritis as a cause of lethal diffuse alveolar hemorrhage.International journal of legal medicine · 2023Article
- Observational Study of Patients Hospitalized With Neurologic Events After SARS-CoV-2 Vaccination, December 2020-June 2021.Neurology. Clinical practice · 2023Article
- An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.Health science reports · 2023Article
- Pharmacological Proposal Approach to Managing Chronic Pain Associated with COVID-19.Biomedicines · 2023Review
- COVID-19 vaccines adverse events: potential molecular mechanisms.Immunologic research · 2023Review
- A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.Vaccines · 2023Review
- Optimal reliability allocation of heterogeneous components in pharmaceutical production plant.International journal on interactive design and manufacturing · 2023Article
- Article
- Safety and Tolerability of COVID-19 Vaccine in Children With Epilepsy: A Prospective, Multicenter Study.Pediatric neurology · 2023Article
- Post-COVID-19 vaccine acute encephalitis in an adult patient: A case report and literature review.Clinical case reports · 2023Article
- From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Article
- Cancerous Patient, COVID-19 Vaccination, Blood Viscosity and Stroke-Like Complication.International journal of preventive medicine · 2023Article
- Guillain-Barre syndrome following COVID-19 vaccines: A review of literature.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 3 countries.
Funding
Abstract
The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic with people infected in almost all countries. The most efficient solution to end this pandemic is a safe and efficient vaccine. Classic platforms are used to develop vaccines including live-attenuated vaccine, inactivated vaccine, protein subunit vaccine, and viral vector. Nucleic acid vaccine uses next-generation platforms for their development. Vaccines are now rushing to the market. Eleven candidates are in advance development. These comprise inactivated vaccines, viral vector vaccine, nucleic acid vaccine, and the protein subunit vaccine platform, which are now quite advanced in trials in various geographic and ethnic populations. The reported severe adverse effects raised the worries about their safety. It becomes critical to know whether these vaccines will cause neurologic disorders like previously recognized vaccine-related demyelinating diseases, fever-induced seizure, and other possible deficits. We reviewed the most promising COVID-2 vaccines with a particular interest in mechanism(s) and adverse effect(s). We exemplify potential neurological problems these vaccines could cause by looking at previous studies. The current evidence indicated a minor risk of the acute neurological disorders after the application. The observation of the long-time effect is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.